50 related articles for article (PubMed ID: 7493366)
1. Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies.
DeNardo GL; Lamborn KR; DeNardo SJ; Goldstein DS; Dolber-Smith EG; Kroger LA; Larkin EC; Shen S
Cancer Res; 1995 Dec; 55(23 Suppl):5893s-5898s. PubMed ID: 7493366
[TBL] [Abstract][Full Text] [Related]
2. Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies.
Lamborn KR; DeNardo GL; DeNardo SJ; Goldstein DS; Shen S; Larkin EC; Kroger LA
Clin Cancer Res; 1997 Aug; 3(8):1253-60. PubMed ID: 9815807
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
Eser B; Sari I; Canoz O; Altuntas F; Cakmak E; Ozturk A; Ozkan M; Er O; Cetin M; Unal A
Am J Hematol; 2006 May; 81(5):307-14. PubMed ID: 16628716
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
7. [Primary gastric lymphoma].
Barreda B F; Gómez P R; Quispe L D; Sánchez L J; Combe G J; Casanova M L; Celis Z J
Rev Gastroenterol Peru; 2004; 24(3):238-62. PubMed ID: 15483686
[TBL] [Abstract][Full Text] [Related]
8. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors in low-grade lymphoma].
Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Zubizarreta A
Sangre (Barc); 1998 Jun; 43(3):185-90. PubMed ID: 9741223
[TBL] [Abstract][Full Text] [Related]
10. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in primary gastric lymphoma.
Medina-Franco H; Germes SS; Maldonado CL
Ann Surg Oncol; 2007 Aug; 14(8):2239-45. PubMed ID: 17546474
[TBL] [Abstract][Full Text] [Related]
12. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
14. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens.
Villela L; López-Guillermo A; Montoto S; Rives S; Bosch F; Perales M; Ferrer A; Esteve J; Colomo L; Campo E; Montserrat E
Cancer; 2001 Apr; 91(8):1557-62. PubMed ID: 11301405
[TBL] [Abstract][Full Text] [Related]
15. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
17. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
18. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
[TBL] [Abstract][Full Text] [Related]
19. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required?
Laskar S; Bahl G; Muckaden MA; Nair R; Gupta S; Bakshi A; Gujral S; Shet T; Shrivastava SK; Dinshaw KA
Cancer; 2007 Aug; 110(4):816-23. PubMed ID: 17582622
[TBL] [Abstract][Full Text] [Related]
20. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
